University of Maryland, School of Medicine, Baltimore, MD, United States.
University of Maryland, School of Medicine, Baltimore, MD, United States.
Neuroimage Clin. 2020;28:102436. doi: 10.1016/j.nicl.2020.102436. Epub 2020 Sep 15.
Numerous studies have used magnetic resonance spectroscopy (MRS) neurometabolite measurements to study HIV infection effects. While many have reported differences in total N-Acetylaspartate (tNAA), myo-Inositol (mI), and total Choline (tCho), there have been no meta-analyses performed to evaluate concordance across studies.
To evaluate the consistency of HIV serostatus effects on brain metabolites.
The sample included studies conducted between 1993 and 2019 reporting HIV infection effects measured using proton MRS. tNAA/tCr ratios (21 papers), tCho/tCr ratios (21 papers), mI/tCr ratios (17 papers) and quantitative tCr (9 papers), sampling from basal ganglia (BG), gray matter (GM), and white matter (WM) were included.
Random effects meta-analysis using inverse variance weighting and bias corrected standardized mean differences (SMDs) was used. Meta-regression examined effects of publication year and data acquisition technique differences.
BG SMDs related to positive serostatus were -0.10 [-0.39; 0.18] tNAA/tCr, 0.27 [0.05; 0.49] tCho/tCr, 0.60 [0.31; 0.90] mI/tCr, and -0.26 [-0.59; 0.06] tCr. GM SMDs related to serostatus were -0.29 [-0.49; -0.09] tNAA/tCr, 0.37 [0.19; 0.54] tCho/tCr, 0.41 [0.15; 0.68] mI/tCr, and -0.24 [-0.45; -0.03] tCr. WM SMDs related to serostatus were -0.52 [-0.79; -0.25] tNAA/tCr, 0.41 [0.21; 0.61] tCho/tCr, 0.59 [0.24; 0.94] mI/tCr, and -0.03 [-0.25; 0.19] tCr. WM regions showed larger serostatus effect sizes than BG and GM. I ranged from 52 to 88% for the metabolite ratios. Both GM and WM tNAA/tCr SMDs were lower with increasing calendar year.
Many studies pooled participants with varying treatment, infection, and comorbidity durations.
HIV neurometabolite studies showed consistently lower tNAA/tCr, higher tCho/tCr and higher mI/tCr ratios associated with chronic HIV infection. Substantial between-study variation may have resulted from measurement technique variations, study population differences and HIV treatment changes over time. Higher WM tCho/tCr and mI/tCr may reflect reactive gliosis or myelin turnover. Neurometabolite measurements can reliably detect chronic HIV infection effects and may be useful in understanding the pathophysiology of cognitive and sensorimotor decline following HIV infection.
This study provides Class II evidence of neurometabolite differences in chronic HIV infection.
许多研究使用磁共振波谱(MRS)神经代谢物测量来研究 HIV 感染的影响。虽然许多研究报告了总 N-乙酰天冬氨酸(tNAA)、肌醇(mI)和总胆碱(tCho)的差异,但尚未进行荟萃分析来评估研究之间的一致性。
评估 HIV 血清阳性状态对脑代谢物的影响的一致性。
该样本包括了 1993 年至 2019 年间进行的研究,报告了使用质子 MRS 测量的 HIV 感染影响。纳入了 tNAA/tCr 比值(21 篇论文)、tCho/tCr 比值(21 篇论文)、mI/tCr 比值(17 篇论文)和定量 tCr(9 篇论文)的研究,采样部位包括基底节(BG)、灰质(GM)和白质(WM)。
采用逆方差加权和偏倚校正标准化均数差(SMD)的随机效应荟萃分析。荟萃回归分析了出版年份和数据采集技术差异的影响。
与阳性血清状态相关的 BG SMD 分别为 -0.10 [-0.39; 0.18] tNAA/tCr、0.27 [0.05; 0.49] tCho/tCr、0.60 [0.31; 0.90] mI/tCr 和 -0.26 [-0.59; 0.06] tCr。与血清状态相关的 GM SMD 分别为 -0.29 [-0.49; -0.09] tNAA/tCr、0.37 [0.19; 0.54] tCho/tCr、0.41 [0.15; 0.68] mI/tCr 和 -0.24 [-0.45; -0.03] tCr。与血清状态相关的 WM SMD 分别为 -0.52 [-0.79; -0.25] tNAA/tCr、0.41 [0.21; 0.61] tCho/tCr、0.59 [0.24; 0.94] mI/tCr 和 -0.03 [-0.25; 0.19] tCr。WM 区域与 BG 和 GM 相比,血清状态的效应大小更大。代谢物比值的 I 范围为 52%至 88%。GM 和 WM tNAA/tCr SMD 随着日历年份的增加而降低。
许多研究将具有不同治疗、感染和合并症持续时间的参与者进行了汇总。
HIV 神经代谢物研究显示,慢性 HIV 感染与持续的 tNAA/tCr 降低、tCho/tCr 升高和 mI/tCr 升高相关。研究之间存在大量的差异,可能是由于测量技术的差异、研究人群的差异以及 HIV 治疗随时间的变化。WM tCho/tCr 和 mI/tCr 的升高可能反映了反应性神经胶质增生或髓鞘周转。神经代谢物测量可以可靠地检测慢性 HIV 感染的影响,并可能有助于理解 HIV 感染后认知和感觉运动能力下降的病理生理学。
本研究提供了 II 级证据,证明了慢性 HIV 感染中神经代谢物的差异。